Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial-Reference-Cited by-同舟云学术

Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial

Published:2019-11 Issue:5 Volume:54 Page:592-600
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Diaz Ricardo Sobhie,Shytaj Iart Luca,Giron Leila B.,Obermaier Benedikt,della Libera Ermelindo,Galinskas Juliana,Dias Danilo,Hunter James,Janini Mario,Gosuen Gisele,Ferreira Paulo Abrão,Sucupira Maria Cecilia,Maricato Juliana,Fackler Oliver,Lusic Marina,Savarino Andrea

Funder

Fundacão de Amparo à Pesquisa do Estado de São Paulo

Brazilian National Research Council

Alexander von Humboldt-Stiftung

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference62 articles.

1. Antibacterial and antivirulence activities of auranofin against Clostridium difficile;AbdelKhalek;Int J Antimicrob Agents,2019

2. Repurposing auranofin for the treatment of cutaneous staphylococcal infections;Thangamani;Int J Antimicrob Agents,2016

3. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo;Hopper;Int J Antimicrob Agents,2016